Axogen to Participate at Upcoming Investor Conferences
03 February 2022 - 11:00PM
Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and
marketing innovative surgical solutions for peripheral nerve
injuries, today announced it will participate in two investor
conferences in February.
Karen Zaderej, chairman, CEO, and president will
participate in a fireside discussion at the BTIG Virtual MedTech,
Digital Health, Life Science & Diagnostic Tools Conference on
Tuesday, February 15, 2022 at 1:25 p.m. ET. To listen to the live
event, please contact your BTIG representative with interest.
Ms. Zaderej will also participate in a fireside
discussion at the virtual 11th Annual SVB Leerink Global Healthcare
Conference on Thursday, February 17, 2022 at 1:40 p.m. ET. The
discussion will be webcast live and can be accessed through the
Investors page at www.axogeninc.com. For those not available to
listen to the live broadcast, a replay will be archived for 90 days
and available through the Investors page on www.axogeninc.com.
About AxogenAxogen (AXGN) is the
leading company focused specifically on the science, development,
and commercialization of technologies for peripheral nerve
regeneration and repair. Axogen employees are passionate about
helping to restore peripheral nerve function and quality of life to
patients with physical damage or transection to peripheral nerves
by providing innovative, clinically proven, and economically
effective repair solutions for surgeons and health care providers.
Peripheral nerves provide the pathways for both motor and sensory
signals throughout the body. Every day, people suffer traumatic
injuries or undergo surgical procedures that impact the function of
their peripheral nerves. Physical damage to a peripheral
nerve, or the inability to properly reconnect peripheral nerves,
can result in the loss of muscle or organ function, the loss of
sensory feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair
features a comprehensive portfolio of products, including Avance®
Nerve Graft, a biologically active off-the-shelf processed human
nerve allograft for bridging severed peripheral nerves without the
comorbidities associated with a second surgical site; Axoguard
Nerve Connector®, a porcine submucosa extracellular matrix (ECM)
coaptation aid for tensionless repair of severed peripheral nerves;
Axoguard Nerve Protector®, a porcine submucosa ECM product used to
wrap and protect damaged peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments; and
Axoguard Nerve Cap®, a porcine submucosa ECM product used to
protect a peripheral nerve end and separate the nerve from the
surrounding environment to reduce the development of symptomatic or
painful neuroma. The Axogen portfolio of products is available in
the United States, Canada, the United Kingdom, South Korea, and
several other European and international countries.
Contact:Axogen,
Inc.Ed Joyce, Director, Investor
Relationsejoyce@axogeninc.comInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024